Serradilla-Martín Mario, Villodre Celia, Falgueras-Verdaguer Laia, Zambudio-Carroll Natalia, Castell-Gómez José T, Blas-Laina Juan L, Borrego-Estella Vicente, Domingo-Del-Pozo Carlos, García-Plaza Gabriel, González-Rodríguez Francisco J, Montalvá-Orón Eva M, Moya-Herraiz Ángel, Paterna-López Sandra, Suárez-Muñoz Miguel A, Alkorta-Zuloaga Maialen, Blanco-Fernández Gerardo, Dabán-Collado Enrique, Gómez-Bravo Miguel A, Miota-de-Llamas José I, Rotellar Fernando, Sánchez-Pérez Belinda, Sánchez-Cabús Santiago, Pacheco-Sánchez David, Rodríguez-Sanjuan Juan C, Varona-Bosque María A, Carrión-Álvarez Lucía, de la Serna-Esteban Sofía, Dopazo Cristina, Martín-Pérez Elena, Martínez-Cecilia David, Castro-Santiago María J, Dorcaratto Dimitri, Gutiérrez-Díaz Marta L, Asencio-Pascual José M, Burdío-Pinilla Fernando, Carracedo-Iglesias Roberto, Escartín-Arias Alfredo, Ielpo Benedetto, Rodríguez-Laiz Gonzalo, Valdivieso-López Andrés, De-Vicente-López Emilio, Alonso-Orduña Vicente, Ramia José M
Department of Surgery, Hospital Universitario Virgen de las Nieves, 18014 Granada, Spain.
Instituto de Investigación Biosanitaria ibs.GRANADA, 18012 Granada, Spain.
Cancers (Basel). 2024 Apr 26;16(9):1676. doi: 10.3390/cancers16091676.
(1) Background: The liver-first approach may be indicated for colorectal cancer patients with synchronous liver metastases to whom preoperative chemotherapy opens a potential window in which liver resection may be undertaken. This study aims to present the data of feasibility and short-term outcomes in the liver-first approach. (2) Methods: A prospective observational study was performed in Spanish hospitals that had a medium/high-volume of HPB surgeries from 1 June 2019 to 31 August 2020. (3) Results: In total, 40 hospitals participated, including a total of 2288 hepatectomies, 1350 for colorectal liver metastases, 150 of them (11.1%) using the liver-first approach, 63 (42.0%) in hospitals performing <50 hepatectomies/year. The proportion of patients as ASA III was significantly higher in centers performing ≥50 hepatectomies/year (difference: 18.9%; = 0.0213). In 81.1% of the cases, the primary tumor was in the rectum or sigmoid colon. In total, 40% of the patients underwent major hepatectomies. The surgical approach was open surgery in 87 (58.0%) patients. Resection margins were R0 in 78.5% of the patients. In total, 40 (26.7%) patients had complications after the liver resection and 36 (27.3%) had complications after the primary resection. One-hundred and thirty-two (89.3%) patients completed the therapeutic regime. (4) Conclusions: There were no differences in the surgical outcomes between the centers performing <50 and ≥50 hepatectomies/year. Further analysis evaluating factors associated with clinical outcomes and determining the best candidates for this approach will be subsequently conducted.
(1) 背景:对于伴有同时性肝转移的结直肠癌患者,肝优先方法可能适用,术前化疗为进行肝切除提供了一个潜在时机。本研究旨在呈现肝优先方法的可行性数据和短期结果。(2) 方法:在2019年6月1日至2020年8月31日期间,对西班牙开展中/高容量肝脏手术的医院进行了一项前瞻性观察研究。(3) 结果:共有40家医院参与,总计2288例肝切除术,其中1350例为结直肠癌肝转移,其中150例(11.1%)采用肝优先方法,63例(42.0%)来自每年肝切除术<50例的医院。每年进行≥50例肝切除术的中心,ASA III级患者比例显著更高(差异:18.9%;P = 0.0213)。81.1%的病例中,原发肿瘤位于直肠或乙状结肠。总计40%的患者接受了大肝切除术。87例(58.0%)患者的手术方式为开放手术。78.5%的患者切缘为R0。总计40例(26.7%)患者肝切除术后出现并发症,36例(27.3%)患者原发灶切除术后出现并发症。132例(89.3%)患者完成了治疗方案。(4) 结论:每年进行<50例和≥50例肝切除术的中心在手术结果上无差异。随后将进一步分析评估与临床结果相关的因素,并确定该方法的最佳适用患者。